Mitomycin C
- CAS No.
- 50-07-7
- Chemical Name:
- Mitomycin C
- Synonyms
- MITOMYCIN;MMC;MITOMYCIN A;AMETYCIN;MITOCIN C;Mitomicin C;azirino(2’,3’:3,4)pyrrolo(1,2-a)indole-4,7-dione,6-amino-1,1a,2,8,8a,8b-hexahy;azirino[2’,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-8-[[(aminocarbonyl)ox;Azirino2,3:3,4pyrrolo1,2-aindole-4,7-dione, 6-amino-8-(aminocarbonyl)oxymethyl-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-;Azirino[2’,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-[1aS-(1aalpha,8beta,8aalpha,8balpha)]-
- CBNumber:
- CB8456544
- Molecular Formula:
- C15H18N4O5
- Molecular Weight:
- 334.33
- MOL File:
- 50-07-7.mol
- Modify Date:
- 2024/8/15 16:24:08
| Melting point | 360 °C |
|---|---|
| Boiling point | 471.14°C (rough estimate) |
| Density | 1.2238 (rough estimate) |
| refractive index | 1.6800 (estimate) |
| storage temp. | 2-8°C |
| solubility | H2O: 4 mL/vial Stock solutions should be filter sterilized and stored at 2-8 °C in the dark., clear to slightly hazy, blue to purple |
| form | powder |
| pka | pKa 2.8(H2O,t =25,I=0.1) (Uncertain) |
| color | blue-gray |
| PH | pH (0.5 g/l, 25℃ : )5.0～7.0 |
| Water Solubility | soluble |
| Merck | 14,6215 |
| BRN | 7231816 |
| Stability | Stable. Incompatible with strong acids, strong bases, strong oxidizing agents. |
| CAS DataBase Reference | 50-07-7(CAS DataBase Reference) |
| IARC | 2B (Vol. 10, Sup 7) 1987 |
| EPA Substance Registry System | Mitomycin C (50-07-7) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS06,GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H300-H351 | |||||||||
| Precautionary statements | P201-P202-P264-P270-P280-P301+P310 | |||||||||
| Hazard Codes | T,Xn,T+ | |||||||||
| Risk Statements | 25-40-22-45-26/27/28 | |||||||||
| Safety Statements | 36/37-45-28A-28-53-22 | |||||||||
| RIDADR | UN 3462 6.1/PG 2 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | CN0700000 | |||||||||
| F | 8-10 | |||||||||
| TSCA | Yes | |||||||||
| HazardClass | 6.1(a) | |||||||||
| PackingGroup | II | |||||||||
| HS Code | 29419090 | |||||||||
| Toxicity | LD50 i.v. in mice: 5 mg/kg (Wakaki); also reported as 9 mg/kg (Kinoshita) | |||||||||
| NFPA 704 |
|
Mitomycin C price More Price(12)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | M7949 | Mitomycin C from Streptomyces caespitosus ≥98% (HPLC), potency: ≥970?μg per mg (USP XXIV), γ-irradiated, suitable for cell culture | 50-07-7 | 2MG | ₹10543.55 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | M0503 | Mitomycin C from Streptomyces caespitosus powder, contains NaCl as solubilizer | 50-07-7 | 2MG | ₹14386.43 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | M4287 | Mitomycin C from Streptomyces caespitosus powder, BioReagent, suitable for cell culture | 50-07-7 | 2MG | ₹15046.75 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | M0503 | Mitomycin C from Streptomyces caespitosus powder, contains NaCl as solubilizer | 50-07-7 | 5X2MG | ₹38731.85 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | M4287 | Mitomycin C from Streptomyces caespitosus powder, BioReagent, suitable for cell culture | 50-07-7 | 5X2MG | ₹67244.9 | 2022-06-14 | Buy |
Mitomycin C Chemical Properties,Uses,Production
Description
Mitomycin C is naturally produced by Streptomyces caespitosus, an Actinobacteria found in soil. Mitomycin C has antibiotic and antitumor activities and has been studied extensively since the 1950s. A unique feature of this drug is strong bioreductive alkylation under hypoxic conditions. Oxygen-poor cells internal to solid tumors provide an environment in which this drug is highly activated. As an antitumor agent, it has shown efficacy in a wide variety of cancers, including gastric cancer, pancreatic cancer, breast cancer, non-small-cell lung cancer, cervical cancer, prostate cancer, and bladder cancer. The sideeffect profile is large, which prohibits its widespread use. Mitomycin C is antibacterial to gram-positive, gram-negative, and acid-fast bacilli.
Chemical Properties
Blue-violet crystals or crystalline powder.
Uses
Mitomycin C is the most studied of a family of highly distinctive blue/purple metabolites produced by several Streptomyces species. Mitomyin C exhibits potent antibacterial and antitumour activity and inhibits DNA synthesis by intercalation, blocking nuclear division with the induction of apoptosis in cancer cells.
Indications
Mitomycin (mitomycin C, Mitocin-C, Mutamycin) is an
antibiotic that is derived from a species of Streptomyces.
It is sometimes classified as an alkylating agent because
it can covalently bind to and cross-link DNA.
Mitomycin is thought to inhibit DNA synthesis through
its ability to alkylate double-strand DNA and bring
about interstrand cross-linking. There is evidence that
enzymatic reduction by a reduced nicotinamide–
adenine dinucleotide phosphate (NADPH) dependent
reductase is necessary to activate the drug.
The drug is rapidly cleared from serum after intravenous
injection but is not distributed to the brain.
Definition
Antibiotic derivedfrom Streptomyces, stated to be effective againsttumors.
General Description
Blue-violet crystals. Used as an anti-tumor antibiotic complex.
Air & Water Reactions
Water soluble.
Reactivity Profile
Mitomycin C is sensitive to prolonged exposure to light. Mitomycin C may be sensitive to prolonged exposure to air. Mitomycin C is incompatible with strong oxidizing agents, strong acids and strong bases. Calcium salts may cause decomposition.
Hazard
Possible carcinogen.
Health Hazard
Toxic doses as low as 750 mg/kg have been reported in humans. The major toxic effect is myelosuppression, characterized by marked leukopenia and thrombocytopenia; this may be delayed and cumulative. Interstitial pneumonia and glomerular damage resulting in kidney failure are unusual but well documented complications. Lung conditions -- administration of mitomycin has been recognized as causing pneumonitis, alveolitis and pulmonary fibrosis. Kidney conditions -- administration of Mitomycin Can cause kidney damage. Kidney toxicity was observed in 1-5 percent of patients. Depressed immune conditions.
Fire Hazard
Flash point data for Mitomycin C are not available; however, Mitomycin C is probably combustible.
Biological Activity
Antibiotic and antitumor agent. Covalently binds DNA forming intra- and interstrand crosslinks. Inhibits DNA synthesis.
Clinical Use
Mitomycin has limited palliative effects in carcinomas of the stomach, pancreas, colon, breast, and cervix.
Side effects
The major toxicity associated with mitomycin therapy is unpredictably long and cumulative myelosuppression that affects both white blood cells and platelets. A syndrome of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure also has been described. Renal, hepatic, and pulmonary toxicity may occur. The drug is teratogenic and carcinogenic, and it can cause local blistering.
Potential Exposure
This compound is an antitumor antibiotic complex. This drug is usually injected intravenously.
Environmental Fate
Mitomycin C is naturally produced by S. caespitosus, a microorganism found in soil and decaying vegetation. As a compound potentially released in commercial solid waste or in spill or container residue, mitomycin C is not thought to persist in soil and water. Calculations based on its hydrolysis rate in water at 25 ℃ show a half-life of 12.9 days. It is readily soluble in water, so mobility in groundwater is high. Mitomycin persistence in air is low and bioaccumulation is low.
Metabolism
Mitomycin is administered IV in the treatment of disseminated adenocarcinoma of the stomach or pancreas, and it has been used intravesically in superficial bladder cancer. Biotransformation pathways are saturable, and approximately 10% of an administered dose is eliminated unchanged via the kidneys.
Shipping
UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required. UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials.
Purification Methods
Mitomycin C forms blue-violet crystals from *C6H6/pet ether. It is soluble in Me2CO, MeOH and H2O, moderately soluble in *C6H6, CCl4 and Et2O but insoluble in pet ether. It has UV max at 216, 360 and a weak peak at 560nm in MeOH. [Stevens et al. J Med Chem 8 1 1965, Shirahata & Hirayama J Am Chem Soc 105 7199 1983, Beilstein 25 III/IV 516.]
Incompatibilities
Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides, heat, strong light, calcium salts.
Waste Disposal
Consult with environmental regulatory agencies for guidance on acceptable disposal practices. Generators of waste containing this contaminant (≥100 kg/mo) must conform to EPA regulations governing storage, transportation, treatment, and waste disposal. It is inappropriate and possibly dangerous to the environment to dispose of expired or waste drugs and pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged, and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
Mitomycin C Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Aspen Biopharma Labs Pvt Ltd | +91-9248058660 +91-9248058662 | Telangana, India | 234 | 58 | Inquiry |
| CONCORD BIOTECH LTD | +91 79 68138700 | New Delhi, India | 18 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
| CONCORD BIOTECH LIMITED | +91 79 68138700 | New Delhi, India | 11 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| Otto Chemie Pvt. Ltd. | +91 9820041841 | Mumbai, India | 5873 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
| Medicea Impex Private Limited | 07942544983 | Nagpur, India | 24 | 58 | Inquiry |
Related articles
- The use of Mitomycin C in the treatment of bladder cancer
- Mitomycin C (MMC) is an alkylating agent that causes DNA damage, including interstrand cross-links and single- or double-stran....
- Apr 12，2024
50-07-7(Mitomycin C)Related Search:
1of4
chevron_right